New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
17:05 EDTMDT, ABIOARCA Biopharma plans new Phase 3 trial for Gencaro
ARCA Biopharma (ABIO) provided an update on a proposed, genetically-targeted clinical trial in atrial fibrillation of the company's lead developmental drug, Gencaro. The company also announced that Medtronic (MDT) has signed a non-binding Letter of Intent to collaborate on the initial, Phase 2B portion of the proposed trial.
News For ABIO;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
09:05 EDTMDTMedtronic receives FDA approval for Attain Performa LV quadripolar leads
Subscribe for More Information
08:33 EDTABIOARCA Biopharma activates first Canadian genetic-AF clinical trial site
Subscribe for More Information
December 10, 2014
08:33 EDTABIOARCA Biopharma receives FDA orphan drug designation for rNaPc2
Subscribe for More Information
December 9, 2014
10:40 EDTABIOARCA Biopharma treatment of Ebola granted orphan designation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use